María Victoria
Mateos Manteca
Profesora Titular de Universidad
Norma Carmen
Gutiérrez Gutiérrez
Profesora Asociada CC. Salud
Publikationen, an denen er mitarbeitet Norma Carmen Gutiérrez Gutiérrez (76)
2024
-
A research center’s experience of T-cell–redirecting therapies in triple-class refractory multiple myeloma
Blood Advances, Vol. 8, Núm. 13, pp. 3478-3487
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology
-
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Blood, Vol. 143, Núm. 7, pp. 597-603
-
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
Haematologica, Vol. 109, Núm. 3, pp. 877-887
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
2023
-
Multiple myeloma with t(11;14): impact of novel agents on outcome
Blood Cancer Journal, Vol. 13, Núm. 1
-
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
Cancers, Vol. 15, Núm. 5
2022
-
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research
-
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710
-
MM-202 Impact of t(11;14) in Multiple Myeloma on Response to Treatment and Survival
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S413-S414
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
-
Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome
British Journal of Haematology, Vol. 199, Núm. 3, pp. 344-354
-
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
Blood cancer journal, Vol. 12, Núm. 4, pp. 76
2021
-
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Blood Cancer Journal, Vol. 11, Núm. 5
2020
-
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Blood, Vol. 135, Núm. 26, pp. 2375-2387
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
-
FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma
Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 7, pp. 4171-4182
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
-
Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
Blood Cancer Journal, Vol. 10, Núm. 2
-
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
Haematologica